Dark Forest Capital Management LP Boosts Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Dark Forest Capital Management LP lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 216.3% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,864 shares of the biotechnology company’s stock after purchasing an additional 38,884 shares during the quarter. Dark Forest Capital Management LP’s holdings in ADMA Biologics were worth $636,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. boosted its holdings in ADMA Biologics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock valued at $7,398,000 after purchasing an additional 27,357 shares during the last quarter. Principal Financial Group Inc. lifted its holdings in ADMA Biologics by 17.7% in the fourth quarter. Principal Financial Group Inc. now owns 158,634 shares of the biotechnology company’s stock valued at $717,000 after acquiring an additional 23,844 shares during the last quarter. Eagle Asset Management Inc. grew its position in ADMA Biologics by 20.2% in the fourth quarter. Eagle Asset Management Inc. now owns 25,957 shares of the biotechnology company’s stock worth $117,000 after acquiring an additional 4,367 shares during the period. Alberta Investment Management Corp increased its stake in ADMA Biologics by 32.4% during the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock worth $2,083,000 after acquiring an additional 112,831 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC raised its position in ADMA Biologics by 19.2% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 143,424 shares of the biotechnology company’s stock valued at $648,000 after purchasing an additional 23,127 shares during the period. Hedge funds and other institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $19.44 on Friday. The stock has a 50-day moving average of $16.27 and a two-hundred day moving average of $11.30. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $20.16. The company has a market cap of $4.51 billion, a P/E ratio of -972.00 and a beta of 0.61.

ADMA Biologics (NASDAQ:ADMA) last released its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The company had revenue of $107.20 million for the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a net margin of 10.53% and a return on equity of 38.79%. The firm’s quarterly revenue was up 78.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.02) EPS. As a group, analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on ADMA shares. HC Wainwright increased their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Finally, Mizuho boosted their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, June 20th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $15.50.

Insider Activity

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the transaction, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. The disclosure for this sale can be found here. Over the last three months, insiders have sold 466,900 shares of company stock worth $8,224,121. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.